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VALIDITY OF THE ADHERENCE ESTIMATOR IN THE PREDICTION OF 
PERSISTENCE WITH CHRNONIC MEDICATIONS ASSESSED OVER 14 
MONTHS
Gadkari A, McHorney C
Merck & Co., Inc., North Wales, PA, USA
OBJECTIVES: Our objective was to assess the predictive validity of the Adherence 
Estimator® (AE), a three-item instrument designed to estimate patients’ propensity to 
adhere to prescription medications for chronic disease. METHODS: The AE was part 
of a larger survey mailed to adults who had an index prescription ﬁll for one of ﬁve 
chronic diseases. Persistence over time was assessed using the continuous measure of 
medication gaps (CMG) from pharmacy claims data. The Wilcoxon rank sum test was 
used to assess differences in median PDC between pairs of the adherence risk groups 
(low/medium/high risk). Sensitivity, speciﬁcity, and positive predictive value (PPV) of 
the AE in the prediction of non-persistence were calculated at 45 days, and three, six, 
nine, 12, and 14 months. Multiple linear regression was used to assess whether the 
AE was a signiﬁcant predictor of persistence at different time intervals, controlling for 
demographics and comorbidity. RESULTS: There were 1,674 usable responses for an 
overall survey response rate of 24.3%. Overall, 42.4% of the respondents were clas-
siﬁed as being at low risk for non-adherence; 35.1% at medium risk; and 22.5% at 
high risk. At 14 months, median therapy gaps (CMG) for the low risk group (38.2%) 
were signiﬁcantly lower than those for the medium-risk (48.7%) and high-risk groups 
(59.1%). At 14 months, sensitivity, speciﬁcity, and PPV for the AE were 61.1%, 
50.5%, and 73.9%, respectively. The sensitivity and the speciﬁcity of the AE remained 
constant over time; the PPV increased as more respondents fell off therapy. Starting 
at three months, the AE risk groups (low vs. medium/high risk) signiﬁcantly predicted 
subsequent gaps in therapy as measured by the CMG. CONCLUSIONS: Patients’ 
propensity to adhere to prescription medications for chronic disease as measured by 
the AE signiﬁcantly predicted patients’ adherence behavior from three to 14 months 
post-index ﬁll.
PHP3
EFFECTIVENESS OF A PATIENT PERSISTENCY PROGRAM TO INCREASE 
COMPLIANCE FOR VACCINATION
Aggarwal S1, Stevens CA2
1PAREXEL Consulting, Bethesda, MD, USA, 2PAREXEL Consulting, Waltham, MA, USA
OBJECTIVES: One of the major challenges with vaccination is achieving high compli-
ance for all required doses of vaccine. Despite strong clinical evidence, policy and 
marketing efforts, the compliance for several vaccination programs remains low. Often 
patients fail to receive the required subsequent doses of the vaccine. We developed 
and tested a persistency program to test its effectiveness in improving patient compli-
ance with vaccines. METHODS: The current compliance rates were reviewed using 
published literature. Information on standard of care was collected from prescribers 
and treatment centers. 10,000 prescribers in a zip code level referral network were 
enrolled. Support system was set up to send telephonic and letter reminders to 90,000 
patients for upcoming appointments. Providers shared reports on patient appoint-
ments allowing for Just-In-Time ordering. We developed billing guides for practices 
identifying commonly used codes. The duration of this study was 1 year. The data for 
number of missed doses and vaccinations were collected for all patients. RESULTS: 
There was a signiﬁcant increase in compliance with patients that were sent reminders 
as part of this persistency program. The 2nd injection compliance was 61% and 3rd 
injection compliance was 42%, which is more than 40%–50% improvement over the 
standard of care. As clinically expected higher compliance led to improved and stable 
titer level in all patients. During feedback surveys, both patients and providers 
reported the beneﬁt of having a support staff that was trained in clinical and reim-
bursement aspects. CONCLUSIONS: Persistency programs can signiﬁcantly improve 
patient compliance by providing support, training and reminders to patients. Such 
programs can improve compliance, achieve better outcomes, save longer term costs 
for payers and collect real-world data.
PHP4
IMPROVING ACCESS-TO-CARE LEADS TO OPTIMAL OUTCOMES IN 
PHARMACIST-LED MEDICATION THERAPY MANAGEMENT (MTM) 
PROGRAM
Pinto S, Holl S
University of Toledo, Toledo, OH, USA
OBJECTIVES: Providing specialized patient care to patients with no insurance can 
enable them to better manage their medications, experience optimal outcomes, and 
ensure more effective use of health care services. This study measured improvement 
in low-income diabetic patient outcomes through participating in a MTM program. 
METHODS: Patients comprised of residents participating in the CareNet program, 
in Lucas County, OH which provides coordinated health care for low-income resi-
dents. Patients received MTM services from their pharmacists on a quarterly basis. 
Patients were provided diabetic supplies, such as lancets and test strips, at no cost 
to encourage participation. The study used a prospective pre-post design following 
patients for a year. Clinical [HbA1c level, systolic blood pressure (SBP), and diastolic 
blood pressure (DBP)] humanistic (patient satisfaction, adherence, knowledge surveys 
and quality of life) and social (caffeine and alcohol consumption, smoking, exercise) 
outcomes were measured at staggered intervals. RESULTS: A total of 100 patients 
were enrolled. Clinical measures. Mean HbA1c concentration decreased from baseline 
to the three-month follow-up. Patients who had an HbA1c level greater than 7% at 
baseline saw a decrease of 0.5% from baseline to three months. Mean SBP and DBP 
values decreased signiﬁcantly from baseline. Patients with a baseline SBP > 
140 mmHg experienced a signiﬁcant change in BP at 3 months (−16 mmHg). Patients 
with a baseline DBP of greater than 90 mmHg experienced a signiﬁcant decrease 
of 16.00 mmHg from baseline. Humanistic measures. Patient knowledge increased 
for all disease states and overall patient satisfaction increased signiﬁcantly. Social 
measures. There was a decrease in caffeine and alcohol consumption, a signiﬁcant 
decrease in smoking, and increase in exercise. Nine month results for all outcomes 
will be presented. CONCLUSIONS: Pharmacists can improve quality of care, access 
to care and positive outcomes for low-income patients in a relatively short amount 
of time.
PHP5
UNCOVERING REASONS OF NON-COMPLIANCE IN EPRO STUDIES TO 
IMPROVE PRO DATA COLLECTION
Ross J, Marcovitz M, Peck R
Almac Clinical Technologies, Yardley, PA, USA
OBJECTIVES: To better understand ways to inﬂuence greater patient compliance in 
providing more accurate data collected via patients during clinical trials. Uncovering 
reasons that patients are not compliant and reviewing measures that electronic patient 
reported outcomes (ePRO) service vendors offer to increase compliance will result in 
an opportunity to overall improve the collection of patient reported outcomes data 
and increase compliance. METHODS: A total of 24 clinical articles from 2001–2009 
were identiﬁed that collected and provided comments on patients’ reasons for non-
compliance of completing patient perspective data during clinical trials. These articles 
were reviewed and the non-compliance information was summarized to help identify 
which reasons were most commonly stated. Measures that many ePRO vendors use 
to help Sponsors increase patient compliance for their studies were identiﬁed. 
The measures offered by ePRO vendors were examined and matched up to reasons 
for non-compliance to identify if there are areas where methods are needed 
for improved patient compliance. RESULTS: Out of the 24 articles reviewed, 
there were 70 responses for non-compliance. Across these responses, there were seven 
major themes (Time, Reminders needed, No access, System issues, Equipment loss, 
Health and Length of study). The most frequent two reasons correlated with Time 
(lack of) and Reminders. In comparing these reasons to available ePRO vendors 
compliance tools, the match-up results were acceptable since reminders (alarms, out-
bound calling) are currently being provided by many, if not all, ePRO vendors. 
Regarding Time, these results really emphasize how important it is not to over burden 
patients with the addition of a diary/assessment to their normal routine. It is clear if 
they reach a point of distress, they apt not to do the diary/assessment. CONCLU-
SIONS: Discussion will include further detail of the non-compliance reasons, major 
themes, tools offered by ePRO vendors and new methods that could be developed 
based on the analysis.
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QUANTITATIVE ANALYSIS OF THE INFLUENCE OF DISEASE AND 
PRODUCT CHARACTERISTICS ON ORPHAN DRUG PRICES IN EUROPE
Aballea S1, Toumi M2, Vataire AL1, Millier A1, Lamure M3
1CREATIV-CEUTICAL, Paris, France, 2University Claude Bernard Lyon 1, Lyon Cedex 08, 
France, 3University Claude Bernard Lyon 1, Paris, France
OBJECTIVES: Speciﬁc regulation and incentives to develop new orphan drugs in US 
and Europe, as well as increased revenues associated with sales of orphan drugs have 
boosted the interest of pharmaceutical companies in this ﬁeld. Pricing is a key success 
factor for manufacturers as sales volumes are very limited. We investigated the deter-
minants of orphan product prices in ﬁve European countries: France, Italy, Germany, 
Spain and UK, using regression analysis. METHODS: Products with orphan designa-
tion approved by EMEA were identiﬁed up to June 2009. Yearly prices per product 
were derived from public prices, WHO deﬁned daily dose, and treatment duration 
based on guidelines or summary product characteristics. The analysis included disease-
related variables: prevalence, disease area, prognosis, age and vulnerability of target 
population, seriousness, number of available treatments and course of illness, and 
drug-related parameters: year of approval, trial size, number of trials, comparator in 
trial, ATC code, evidence of beneﬁt. A generalized linear model was used to identify 
price predictors for the 5 countries. RESULTS: Fifty-one products were identiﬁed of 
which respectively 37, 35, 28, 36 and 39 were available in France, Germany, Italy, 
Spain and UK respectively. Available products did not overlap across countries. Prices 
were highest in Italy and lowest in UK. No signiﬁcant correlation was found between 
any of the variables and price. Low prevalence and low number of available treatment 
alternatives seemed associated with high prices, but these trends were not statistically 
signiﬁcant. CONCLUSIONS: Pricing of orphan drugs is a complex process, with no 
identiﬁable objective price determinant. Patient group pressure, low overall impact on 
health care expenditure budget, inﬂuence of opinion leaders and the ability of leverag-
ing the importance of unmet need in the target population might play an important 
role. This analysis generated hypotheses for further research into drivers of prices for 
orphan drugs.
